Drug Trial Radar · NCT04758767
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Mar 22, 2021
Primary completion
Jan 19, 2023
Study completion Jan 19, 2023
Sponsor
- Lead sponsor
- CASI pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once the recommended CID-103 dose and infusion duration is known, additional patients will be enrolled in an expansion phase consisting of two cohorts (anti-CD38 pretreated, and anti-CD38 treatment naïve). Patients will be treated until disease progression or unacceptable toxicities.
Conditions
- Multiple Myeloma
Interventions
CID-103Drug
anti-CD38 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: approximately 18 months after study start
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
CHU de Nantes - Hôpital Hôtel-Dieu
Nantes, France
CHU Rennes - Pontchaillou
Rennes, France
Gustave Roussy Cancer Center
Villejuif, France
Sarah Cannon
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.